ArticleParasitology research2011
Measurement of naturally acquired humoral immune responses against the C-terminal region of the Plasmodium vivax MSP1 protein using protein arrays.
Article in Parasitology research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- Comparative evaluation of four immunoassays for Plasmodium vivax serological detection using recombinant PvMSP1-42 antigen.PLoS neglected tropical diseases · 2026Article
- Cross-species reactivity of antibodies against Plasmodium vivax blood-stage antigens to Plasmodium knowlesi.PLoS neglected tropical diseases · 2020Article
- Evaluation of antibody responses to the early transcribed membrane protein family in Plasmodium vivax.Parasites & vectors · 2019Article
- What Is Known about the Immune Response Induced byFrontiers in immunology · 2017Review
- Characterization of Pv92, a Novel Merozoite Surface Protein of Plasmodium vivax.The Korean journal of parasitology · 2016Article
- Identification of a reticulocyte-specific binding domain of Plasmodium vivax reticulocyte-binding protein 1 that is homologous to the PfRh4 erythrocyte-binding domain.Scientific reports · 2016Article
- Maternal-foetal transfer of Plasmodium falciparum and Plasmodium vivax antibodies in a low transmission setting.Scientific reports · 2016Article
- Immunoprofiling of the tryptophan-rich antigen family in Plasmodium vivax.Infection and immunity · 2015Article
- CD4+ T cell response correlates with naturally acquired antibodies against Plasmodium vivax tryptophan-rich antigens.Infection and immunity · 2015Article
- Serological responses to a soluble recombinant chimeric Plasmodium vivax circumsporozoite protein in VK210 and VK247 population.Malaria journal · 2013Article
- The Plasmodium vivax merozoite surface protein 1 paralog is a novel erythrocyte-binding ligand of P. vivax.Infection and immunity · 2013Article
- Identification and characterization of the Plasmodium falciparum RhopH2 ortholog in Plasmodium vivax.Parasitology research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein arrays are powerful tools for antibody profiling and vaccine development against infectious agents. In the previous report, we successfully applied an antibody-based protein array for immunoprofiling of Plasmodium vivax infection. Herein, we developed a Ni-NTA surface based protein array to detect immune responses against the recombinant C-terminal region (19 and 42 kDa) of the P. vivax merozoite surface protein 1 (PvMSP1-19 and -42) from sera of vivax malaria patients. The PvMSP1-19 arrays detected P. vivax in 112 of 130 (86.2%; 95% CI, 83.2-89.2%) microscopically positive samples and 2 false positives were obtained among 100 sera samples from healthy subjects (2.0%; 95% CI, 0.6-3.4%). These results were in concordance with results of enzyme-linked immunosorbent assays (ELISA). Kappa values represented excellent agreement for the recombinant PvMSP1-19 protein against sera samples as measured by protein arrays and ELISA (Kappa=0.904, 95% CI: 0.849-0.960). The PvMSP1-42 protein arrays detected antibody response in 100 of 130 microscopically positive samples (76.9%; 95% CI, 72.4-86.8%) and 8 false positives were obtained in 100 healthy subjects (8.0%; 95% CI, 2.7-13.3%). There is no significant difference between the fluorescent intensity of antibody response to PvMSP1-19 and PvMSP1-42 in the positive sera samples (P>0.05). The novel protein array platform may be used for profiling naturally acquired humoral immune responses to P. vivax infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.